Macrophage Density Predicts Facial Nerve Outcome and Tumor Growth after Subtotal Resection of Vestibular Schwannoma

Abstract

Introduction Vestibular schwannoma (VS) behavior following subtotal resection (STR) is highly variable. Overall progression rates have been reported as high as 44%, and optimal treatment is controversial. Correspondingly, identification of a reliable clinical or pathologic marker associated with progression after STR would help guide decision-making.

Methods A prospectively maintained institutional VS registry from 1999 to 2014 was retrospectively reviewed for sporadic VS patients who underwent primary STR without preceding stereotactic radiosurgery (SRS) by a single neurosurgery-neurotology team. Primary endpoints included tumor progression and postoperative facial nerve function. Pathologic specimens were stained for Ki67, CD68, S100, and SOX10 and were quantitated by digital imaging analysis. Macrophage density was defined as the ratio of CD68⁺ macrophages to S100⁺ macrophages and Schwannian tumor cells. Clinical outcomes were correlated with pathologic markers.

Results Forty-six patients met the study inclusion criteria. Thirteen (28%) progressed during a mean 57 months of follow-up (range 15–149). Favorable postoperative facial nerve function (House–Brackmann I–II) was achieved in 37 (80%). CD68⁺ cells were present at significantly higher concentrations in tumors that progressed (p = 0.03). Higher macrophage density was significantly associated with both tumor progression (p = 0.02) and unfavorable facial nerve function (p = 0.02). Ki67 percent positivity was not significantly associated with either primary endpoint (p = 0.83; p = 0.58).

Conclusions Macrophage density may provide an important marker for individuals at the highest risk for progression of VS after STR, potentially prompting closer surveillance or consideration for upfront SRS following STR. This finding supports preceding conclusions that an intratumoral macrophage-predominant inflammatory response may be a marker for tumor growth and a potential therapeutic target.

Keywords

vestibular schwannoma - subtotal resection - tumor recurrence - tumor progression - macrophages - macrophage density

Financial Material and Support

Internal departmental funding was utilized without commercial sponsorship or support.

Previous Presentation

Components of this manuscript were presented at the North American Skull Base Society 2017 annual meeting

• References

• 1 Ahmad RA, Sivalingam S, Topsakal V, Russo A, Taibah A, Sanna M. Rate of recurrent vestibular schwannoma after total removal via different surgical approaches. Ann Otol Rhinol Laryngol 2012; 121 (03) 156-161
• 2 El-Kashlan HK, Zeitoun H, Arts HA, Hoff JT, Telian SA. Recurrence of acoustic neuroma after incomplete resection. Am J Otol 2000; 21 (03) 389-392
• 3 Freeman SR, Ramsden RT, Saeed SR. , et al. Revision surgery for residual or recurrent vestibular schwannoma. Otol Neurotol 2007; 28 (08) 1076-1082
• 4 Hong B, Krauss JK, Bremer M, Karstens JH, Heissler HE, Nakamura M. Vestibular schwannoma microsurgery for recurrent tumors after radiation therapy or previous surgical resection. Otol Neurotol 2014; 35 (01) 171-181
• 5 Jacob JT, Carlson ML, Driscoll CL, Link MJ. Volumetric analysis of tumor control following subtotal and near-total resection of vestibular schwannoma. Laryngoscope 2016; 126 (08) 1877-1882
• 6 Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery 1997; 40 (01) 1-9 , discussion 9–10
• 7 Roberson Jr JB, Brackmann DE, Hitselberger WE. Acoustic neuroma recurrence after suboccipital resection: management with translabyrinthine resection. Am J Otol 1996; 17 (02) 307-311
• 8 Samii M, Gerganov VM, Samii A. Functional outcome after complete surgical removal of giant vestibular schwannomas. J Neurosurg 2010; 112 (04) 860-867
• 9 Samii M, Matthies C, Tatagiba M. Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 1997; 40 (04) 696-705 , discussion 705–706
• 10 Pollock BE, Lunsford LD, Flickinger JC, Clyde BL, Kondziolka D. Vestibular schwannoma management. Part I. Failed microsurgery and the role of delayed stereotactic radiosurgery. J Neurosurg 1998; 89 (06) 944-948
• 11 Samii M, Metwali H, Gerganov V. Microsurgical management of vestibular schwannoma after failed previous surgery. J Neurosurg 2016; 125 (05) 1198-1203
• 12 Iwai Y, Ishibashi K, Watanabe Y, Uemura G, Yamanaka K. Functional preservation after planned partial resection followed by gamma knife radiosurgery for large vestibular schwannomas. World Neurosurg 2015; 84 (02) 292-300
• 13 Monfared A, Corrales E, Theodosopoulos P. , et al. Facial nerve outcome and tumor control rate as a function of degree of resection in treatment of large acoustic neuromas: preliminary report of the Acoustic Neuroma Subtotal Resection Study (ANSRS). Neurosurgery 2016; 79 (02) 194-203
• 14 van de Langenberg R, Hanssens PE, van Overbeeke JJ. , et al. Management of large vestibular schwannoma. Part I. Planned subtotal resection followed by Gamma Knife surgery: radiological and clinical aspects. J Neurosurg 2011; 115 (05) 875-884
• 15 Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30 (07) 1073-1081
• 16 Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008; 222: 155-161
• 17 Allen M, Louise Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 2011; 223 (02) 162-176
• 18 de Vries M, Briaire-de Bruijn I, Malessy MJ, de Bruïne SF, van der Mey AG, Hogendoorn PC. Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas. Otol Neurotol 2013; 34 (02) 347-352
• 19 Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27: 451-483
• 20 Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86 (05) 1065-1073
• 21 de Vries M, Hogendoorn PC, Briaire-de Bruyn I, Malessy MJ, van der Mey AG. Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas. Virchows Arch 2012; 460 (06) 629-636
• 22 Monsell EM. New and revised reporting guidelines from the Committee on Hearing and Equilibrium. American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc. Otolaryngol Head Neck Surg 1995; 113 (03) 176-178
• 23 House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg 1985; 93 (02) 146-147
• 24 Gomez-Brouchet A, Delisle MB, Cognard C. , et al. Vestibular schwannomas: correlations between magnetic resonance imaging and histopathologic appearance. Otol Neurotol 2001; 22 (01) 79-86
• 25 Niemczyk K, Vaneecloo FM, Lecomte MH. , et al. Correlation between Ki-67 index and some clinical aspects of acoustic neuromas (vestibular schwannomas). Otolaryngol Head Neck Surg 2000; 123 (06) 779-783
• 26 Lee DJ, Westra WH, Staecker H, Long D, Niparko JK, Slattery III WH. Clinical and histopathologic features of recurrent vestibular schwannoma (acoustic neuroma) after stereotactic radiosurgery. Otol Neurotol 2003; 24 (04) 650-660 , discussion 660
• 27 Pollock BE. Management of vestibular schwannomas that enlarge after stereotactic radiosurgery: treatment recommendations based on a 15 year experience. Neurosurgery 2006; 58 (02) 241-248 , discussion 241–248
• 28 Coward J, Kulbe H, Chakravarty P. , et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011; 17 (18) 6083-6096
• 29 Hagemann T, Lawrence T, McNeish I. , et al. “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008; 205 (06) 1261-1268
• 30 Pander J, Heusinkveld M, van der Straaten T. , et al. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res 2011; 17 (17) 5668-5673
• 31 Kandathil CK, Dilwali S, Wu C-C. , et al. Aspirin intake correlates with halted growth of sporadic vestibular schwannoma in vivo. Otol Neurotol 2014; 35 (02) 353-357
• 32 Kandathil CK, Cunnane ME, McKenna MJ, Curtin HD, Stankovic KM. Correlation between aspirin intake and reduced growth of human vestibular schwannoma: volumetric analysis. Otol Neurotol 2016; 37 (09) 1428-1434
• 33 Dilwali S, Kao SY, Fujita T, Landegger LD, Stankovic KM. Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas. Transl Res 2015; 166 (01) 1-11